Policy | August 27, 2024
India's bioeconomy to reach US $300 billion by 2030: Dr. Jitendra Singh
The new bioeconomy policy rolled out by the Modi government is set to place India as a global leader in the years to come
The new bioeconomy policy rolled out by the Modi government is set to place India as a global leader in the years to come
The updated COVID-19 vaccine is tailored to the KP.2 strain of the SARS-CoV-2 Omicron JN.1 lineage and is recommended for individuals 6 months of age and older
Novartis has option to acquire two future development-ready programs to augment its renal portfolio, a strategic area of focus for the company
Collaboration with KNAUER to streamline and improve the scale-up of LNP formulations
CureVac receives €400 million upfront and up to an additional €1.05 billion in development, regulatory and sales milestone payments as well as tiered royalties; all previous financial considerations from the prior collaboration agreement replaced
_256_384.jpg)
Cipla had earlier invested € 15 million in Ethris in 2022
Higher efficacy was observed in mRNA-1283 compared to Spikevax in adults 18 years of age and older
mRESVIA is Moderna's second approved product and the only RSV vaccine available in single-dose pre-filled syringes
Acquisition will advance Merck’s integrated offering for viral vector manufacturing
U.S. FDA has informed Moderna that due to administrative constraints, the agency will not complete its review of mRNA-1345 by the PDUFA date of May 12, 2024
Subscribe To Our Newsletter & Stay Updated
